Oxygen therapy via high flow nasal cannula in pediatric intensive care unit

Oto, Arzu; Erdoğan, Seher; Boşnak, Mehmet

doi:10.24953/turkjped.2016.04.005

Cited by 13 publications

(11 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…HFNC is a relatively effective and safe non-invasive ventilation model in the pediatric ward, Emergency Department, and PICU (13,19). It was recently accepted as a treatment option for noninvasive ventilation or before endotracheal intubation (14,(20)(21)(22).…”

Section: Discussionmentioning

confidence: 99%

“…The clinical diagnostic criteria of pneumonia are acute infection of lung parenchyma and / or pulmonary interstitium, causing varying degrees of hypoxia and infection symptoms, usually accompanied by fever, cough, shortness of breath, lung moist rales, abnormal chest X changes (19).The imaging evidence of pneumonia is consolidation (with or without dense or fluffy opacity of bronchography), other infiltration (linear and patchy alveolar or interstitial density), or pleural effusion. Severe pneumonia is characterized by cyanosis, shortness of breath, RR ≥ 70 per min (infant) or RR ≥ 50 per min (over 1 year old), assisted breathing (groan, nasal fan, trigeminal sign), intermittent apnea or oxygen saturation <92%.…”

Section: Patientsmentioning

confidence: 99%

See 1 more Smart Citation

High-Flow Nasal Cannula vs. Continuous Positive Airway Pressure Therapy for the Treatment of Children <2 Years With Mild to Moderate Respiratory Failure Due to Pneumonia

Liu

Cheng

et al. 2020

Front. Pediatr.

View full text Add to dashboard Cite

Background: The aim of this prospective randomized controlled study was to further compare the clinical benefits and adverse reactions of HFNC with CPAP in the treatment of mild to moderate respiratory failure due to pneumonia in children below 2 years old. Methods: Using a prospective randomized controlled study method, 84 patients with pneumonia and mild to moderate respiratory failure admitted to the Children's Hospital Affiliated to Chongqing Medical University from January 2018 to December 2019 were randomly divided into the HFNC group and the CPAP group. It was registered as a clinical trial at clinical trials.gov , registration number: ChiCTR2000030463. Results: The analyses included 84 patients. No differences were observed between the two groups in baseline demographic or physiological characteristics. Treatment failure necessitating intubation and transfer to the PICU was noted in six of 43 infants (14%) in the HFNC group, as compared with four of 41 infants (10%) in the CPAP group ( P > 0.05). There were no significant differences between the two groups in the duration of hospital stay, the duration of non-invasive respiratory support, and mortality. The 10 infants who experienced treatment failure had more severe hypoxemia with lower PaO2/FiO2 (HFNC 182 ± 11.5 and CPAP 172 ± 8.6). We found that both the HFNC group and the CPAP group showed significantly improved oxygenation and relief of respiratory distress after treatment. No differences were observed between the two groups in the development improvement of RR, PaO2, PaCO2, SpO2, and PH. Assessment of the occurrence of adverse events showed that the HFNC group had a lower level of nasal injury, a lower risk of abdominal distension, a lower intensity and frequency of sedation, and better tolerance. Conclusion: HFNC is an effective and safe initial respiratory support treatment in children <2 years with mild to moderate respiratory failure due to pneumonia, and the incidence of intubation and death is very low; concurrently, the comfort and tolerance of HFNC are better. To some extent, HFNC is a well-tolerated alternative to CPAP.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Patientsmentioning

confidence: 99%

High-Flow Nasal Cannula vs. Continuous Positive Airway Pressure Therapy for the Treatment of Children <2 Years With Mild to Moderate Respiratory Failure Due to Pneumonia

Liu

Cheng

et al. 2020

Front. Pediatr.

View full text Add to dashboard Cite

show abstract

“…Durante el estudio, todos los pacientes manejados con CNAF iniciaron con un flujo a 2 l/kg/min con su posterior ajuste para mantener una SO 2 mayor a 94%. La tasa de éxito en pacientes menores de 5 años con insuficiencia respiratoria secundaria a patologías respiratorias en nuestro estudio fue de 86%, similar a lo descrito en la literatura por Kamit et al 2 , Oto et al 14 y Wing et al 24 siendo 87%, 80% y 84%, respectivamente.…”

Section: Discussionunclassified

“…[4][5][6][7][8][9][10][11] La mayoría de los estudios de la terapia con CNAF han sido realizados en neonatos o en el periodo de postextubación en lactantes con bronquiolitis 12 . Cada vez hay más estudios en población pediátrica que reportan que el uso de la CNAF es un tratamiento eficaz para la insuficiencia respiratoria aguda 4,5,[13][14][15] . Sin embargo, los estudios que evalúan la efectividad de la CNAF en niños con diversas etiologías de dificultad respiratoria entre 1 mes y 18 años de edad en UCIP son muy limitados.…”

Section: Introductionunclassified

Eficacia de la Cánula Nasal de Alto Flujo en patologías respiratorias

Caparó¹,

Antonio²,

Dutari³

et al. 2021

Pediatr Panama

View full text Add to dashboard Cite

Introducción: En la edad pediátrica hay factores predisponentes importantes que hacen a los niños ser más vulnerables a presentar insuficiencia respiratoria aguda (IRA). Objetivo: Demostrar los beneficios del uso de la cánula nasal de alto flujo (CNAF) en pacientes menores de 5 años con IRA secundaria a enfermedades respiratorias y admitidos a la unidad de cuidados intensivos pediátricos (UCIP). Sujetos y Métodos: Estudio analítico observacional de cohortes mixtas, donde una cohorte esta formada por un grupo expuesto a la CNAF evaluada de manera prospectiva, mientras se comparo con una cohorte histórica. Resultados: 138 pacientes fueron admitidos al estudio de los cuales 69 fueron casos manejados con CNAF y 69 fueron controles que no estuvieron expuestos al uso de la CNAF pero sí a otros modos de ventilación mecánica invasiva. Los días de oxigenoterapia fueron estadísticamente menores en el grupo de casos de 13 (DE 8.01) días a 22 (DE 20.7) días en el grupo control (P = <0.05). Al igual los días de UCIP y los días totales de hospitalización fueron menores en el grupo manejado con CNAF (P = 0.011 y P = 0.001, respectivamente), con una media de tiempo de 10 (DE 7.8) días en UCIP y 17 (DE 9.25) días intrahospitalarios para el grupo de casos versus 14 (DE 10.1) días en UCIP y 28 (DE 23.9) días intrahospitalarios para el grupo control. Conclusión: La CNAF es un método de soporte respiratorio no invasivo, efectivo y fácil de usar en la población pediátrica con IRA secundario a diversas patologías respiratorias.

show abstract

“…Bronşiyolit endikasyonuyla YANKO tedavisi uygulanan hastalarda yapılan diğer bir çalışmada da 12 ay ve altındaki 58 bebekten birinde entübasyon ve mekanik ventilasyon desteği ile düzelen pnömotoraks bildirilmiştir (9). Oto ve arkadaşları yaptıkları çalışmada, çocuk yoğun bakım ünitesinde akut hipoksemik solunum yetmezliği nedeniyle YANKO tedavisi uyguladıkları 50 hastanın hiçbirinde hava kaçağı sendromuna rastlamadıklarını bildirmişlerdir (10).…”

Section: Discussionunclassified

A complication of high flow nasal cannula oxygenation therapy: Pneumothorax

2020

Jour Umraniye Pediatr

View full text Add to dashboard Cite

High flow nasal cannula oxygenation (HFNC) therapy is a safe and comfortable treat-ment method that has been widely used in both pediatric and adult patients in recent years. A two-month-old male patient admitted to our emergency department was hospita-lized with a pre-diagnosis of acute bronchiolitis, and HFNC treatment was started due to respiratory distress. Pneumothorax was observed in the chest radiography of the patient who developed tachypnea and dyspnea during follow-up. Underwater drainage was per-formed by inserting a thorax catheter. The thoracic catheter was removed due to clinical and radiological improvement on the fifth day of the treatment. With this case report; We wanted to emphasize that although it is a rare complication during HFNC treatment, pneumothorax may develop and the patient should be followed closely.

show abstract

Oxygen therapy via high flow nasal cannula in pediatric intensive care unit

Cited by 13 publications

References 21 publications

High-Flow Nasal Cannula vs. Continuous Positive Airway Pressure Therapy for the Treatment of Children <2 Years With Mild to Moderate Respiratory Failure Due to Pneumonia

High-Flow Nasal Cannula vs. Continuous Positive Airway Pressure Therapy for the Treatment of Children <2 Years With Mild to Moderate Respiratory Failure Due to Pneumonia

Eficacia de la Cánula Nasal de Alto Flujo en patologías respiratorias

A complication of high flow nasal cannula oxygenation therapy: Pneumothorax

Contact Info

Product

Resources

About